Credit Suisse Group restated their outperform rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a report issued on Thursday. The brokerage currently has a $55.00 price target on the biopharmaceutical company’s stock.
A number of other research firms have also recently commented on XLRN. HC Wainwright increased their target price on Acceleron Pharma from $57.00 to $62.00 and gave the stock a buy rating in a research note on Tuesday, November 7th. Oppenheimer reissued a hold rating on shares of Acceleron Pharma in a research note on Monday, December 11th. Barclays increased their target price on Acceleron Pharma from $42.00 to $50.00 and gave the stock an overweight rating in a research note on Wednesday, September 20th. ValuEngine cut Acceleron Pharma from a hold rating to a sell rating in a research note on Friday, October 6th. Finally, Cann reissued a hold rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. Acceleron Pharma presently has an average rating of Buy and an average target price of $44.81.
Acceleron Pharma (NASDAQ:XLRN) traded up $0.69 during midday trading on Thursday, hitting $43.04. The stock had a trading volume of 197,438 shares, compared to its average volume of 275,733. Acceleron Pharma has a 52-week low of $23.07 and a 52-week high of $46.93. The stock has a market capitalization of $1,915.70, a PE ratio of -16.62 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. During the same period in the prior year, the firm posted ($0.55) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. equities analysts expect that Acceleron Pharma will post -2.65 earnings per share for the current year.
In related news, Director Jean George sold 105,122 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the sale, the director now directly owns 1,250 shares of the company’s stock, valued at $44,662.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the transaction, the chief financial officer now directly owns 45,300 shares in the company, valued at approximately $1,942,917. The disclosure for this sale can be found here. Insiders have sold 146,021 shares of company stock worth $5,529,598 over the last ninety days. 3.90% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Acceleron Pharma by 9.0% in the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after acquiring an additional 330,635 shares during the period. Vanguard Group Inc. lifted its holdings in Acceleron Pharma by 6.1% in the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after acquiring an additional 116,705 shares during the period. Perceptive Advisors LLC lifted its holdings in Acceleron Pharma by 127.2% in the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after acquiring an additional 905,000 shares during the period. State Street Corp lifted its holdings in Acceleron Pharma by 9.4% in the second quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after acquiring an additional 97,199 shares during the period. Finally, Sectoral Asset Management Inc lifted its holdings in Acceleron Pharma by 378.2% in the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after acquiring an additional 478,099 shares during the period. 85.70% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/01/20/acceleron-pharma-xlrn-given-outperform-rating-at-credit-suisse-group.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.